For the nFP treatments, 2 different 1550-nm glass-fiber lasers were used (Fraxel 750 and Fraxel re:store; Reliant Technologies Inc, Clear View, California). The first 3 treatments were done with the Fraxel 750 device at a microbeam energy of 16 mJ per microthermal treatment zone (MTZ) and a final MTZ density of 1250 MTZ/cm2 delivered in 10 passes at 125 MTZ/cm2 per pass. Two subsequent treatments were executed with a Fraxel restore device, an upgraded instrument model from the same manufacturer, at a fluence of 35 and 40 mJ/MTZ, treatment level 8, and 8 passes. Local anesthesia was achieved by 60-minute incubation without occlusion of a custom-made topical anesthetic cream containing lidocaine, 23%, tetracaine hydrochloride, 3.5%, and tetracaine base, 3.5%. Furthermore, a forced-air cooling device (Zimmer Cooling Device; Medizin Systems, Irvine, California) was used on a setting of 3 during the laser exposure to reduce discomfort and the potential risk of bulk heating.